| Cat.No. | Name | Information |
|---|---|---|
| M3517 | Lapatinib | Lapatinib (GW572016) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
| M1802 | Lapatinib ditosylate monohydrate | Lapatinib (GW572016) ditosylate monohydrate is a selective and effective inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM) and ErbB-4 kinase (Ki = 347 nM). |
| M1749 | Gefitinib | Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. |
| M5621 | Erlotinib (CP-358774) | Erlotinib (CP-358774) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
| M1913 | Neratinib | Neratinib (HKI-272) is an orally available, irreversible inhibitor of Her 2 tyrosine kinase. |
| M1850 | WZ4002 | WZ4002 is a novel, selective EGFR kinase inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) with IC50 of 8 nM. |
| M1869 | Dacomitinib | Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases. |
| M5307 | Afatinib dimaleate | Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. |
| M2424 | AZD9291 (Osimertinib) | Osimertinib (AZD-9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR, respectively. |
| M1677 | Afatinib | Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor. |
| M9400 | Firmonertinib mesylate | Firmonertinib (Alflutinib) mesylate is a potent, third generation EGFR inhibitor that targets both EGFR activating mutations and T790M thus leading to tumor growth inhibition. Firmonertinib (AST2818) has the potential for the research of non-small cell lung cancer (NSCLC). |
| M9132 | ABM-3627 | ABM-3627, also known as Mutant EGFR inhibitor, is a selective and potent Mutated EGFR inhibitor. |
| M8818 | Tyrphostin RG 13022 | RG13022 is a non-phenolic tyrphostin-class tyrosine kinase inhibitor. |
| M6162 | MTX-211 | MTX-211 (Mol 211) is a dual inhibitor of EGFR and PI3K with IC50 values of ＜100 nM. MTX-211 is a enamide hydrate. |
| M6103 | Cetuximab | Cetuximab is a chimeric IgG1 monoclonal antibody to EGFR that inhibits the interaction of EGFR with its ligand. For use in cellular assays, human IgG antibody can be used as an isotype control. (For human and non-humanized mice). |
| M6081 | EAI045 | EAI045 is a fourth generation allosteric inhibitor of mutant EGFR, which inhibits EGFR at 10 μM ATP, EGFRL858R, EGFRT790M and EGFRL858R/T790M with IC50 values of 1.9, 0.019, 0.19 and 0.002 μM respectively. |
| M5679 | Gefitinib HCl | Gefitinib Hcl(ZD-1839 Hcl) is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR. |
| M5346 | WZ3146 | WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I). |
| M5318 | Zoligratinib | CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1. |
| M5286 | Acrivastine | Acrivastine is a novel antihistamine compound whose peripheral Hi-antagonist has the same potency as trichloropyridine, but doses of up to 4mg of atorvastatin do not reduce alert performance or increase response time. reaction time. |
| M5275 | Nazartinib | Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild type (wt) EGFR in vitro. |
| M5133 | Olmutinib | Olmutinib is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK). |
| M5127 | FIIN-2 | FIIN-2 is an irreversible, pan-FGFR inhibitor with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM for FGFR1/2/3/4, respectively. |
| M5099 | Osimertinib mesylate (AZD-9291 mesylate) | Osimertinib mesylate (AZD-9291 mesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. |
| M5031 | Poziotinib | Poziotinib (NOV120101; HM781-36B) is an irreversible Pan-HER inhibitor with IC50s of 3/5/23 nM for HER1/HER2/HER4 respectively. |
| M4871 | CL-387785 | CL-387785 (EKI-785) is an irreversible, and selective EGFR inhibitor with IC50 of 370 pM. |
| M4850 | PD153035 | PD153035 is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM. |
| M4805 | BIBX 1382 | BIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM). |
| M4749 | Cyasterone | Cyasterone, a natural EGFR inhibitor, was primarily isolated from Ajuga Decumbens Thunb (Labiatae). Cyasterone showed antiproliferative effects by inducing apoptosis and cell cycle arrest. Cyasterone could be used in studies against human tumors. |
| M4208 | (-)-Epigallocatechin gallate | (-)-Epigallocatechin Gallate is an antioxidant polyphenol flavonoid form green tea, and inhibits the activation of EGFR, HER2 and HER3, with antitumor activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
